These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 23719681)

  • 1. Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.
    Diao L; Meibohm B
    Clin Pharmacokinet; 2013 Oct; 52(10):855-68. PubMed ID: 23719681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to improve the physicochemical properties of peptide-based drugs.
    Lee MF; Poh CL
    Pharm Res; 2023 Mar; 40(3):617-632. PubMed ID: 36869247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.
    Dostalek M; Gardner I; Gurbaxani BM; Rose RH; Chetty M
    Clin Pharmacokinet; 2013 Feb; 52(2):83-124. PubMed ID: 23299465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism of Peptide Drugs and Strategies to Improve their Metabolic Stability.
    Yao JF; Yang H; Zhao YZ; Xue M
    Curr Drug Metab; 2018; 19(11):892-901. PubMed ID: 29956618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current strategies in extending half-lives of therapeutic proteins.
    Zaman R; Islam RA; Ibnat N; Othman I; Zaini A; Lee CY; Chowdhury EH
    J Control Release; 2019 May; 301():176-189. PubMed ID: 30849445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs.
    Czock D; Keller F; Seidling HM
    Br J Clin Pharmacol; 2012 Jul; 74(1):66-74. PubMed ID: 22242561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic properties of tandem d-peptides designed for treatment of Alzheimer's disease.
    Leithold LH; Jiang N; Post J; Niemietz N; Schartmann E; Ziehm T; Kutzsche J; Shah NJ; Breitkreutz J; Langen KJ; Willuweit A; Willbold D
    Eur J Pharm Sci; 2016 Jun; 89():31-8. PubMed ID: 27086111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody.
    Kielbasa W; Helton DL
    Cephalalgia; 2019 Sep; 39(10):1284-1297. PubMed ID: 30917684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic aspects of biotechnology products.
    Tang L; Persky AM; Hochhaus G; Meibohm B
    J Pharm Sci; 2004 Sep; 93(9):2184-204. PubMed ID: 15295780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of Protein and Peptide Drugs Based on the Mechanisms of Kidney Clearance.
    Wu H; Huang J
    Protein Pept Lett; 2018; 25(6):514-521. PubMed ID: 29848260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in therapeutic peptides targeting G protein-coupled receptors.
    Davenport AP; Scully CCG; de Graaf C; Brown AJH; Maguire JJ
    Nat Rev Drug Discov; 2020 Jun; 19(6):389-413. PubMed ID: 32494050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating peptide half-life in serum from tunable, sequence-related physicochemical properties.
    Cavaco M; Valle J; Flores I; Andreu D; A R B Castanho M
    Clin Transl Sci; 2021 Jul; 14(4):1349-1358. PubMed ID: 33641212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimuli-Responsive Polymeric Systems for Controlled Protein and Peptide Delivery: Future Implications for Ocular Delivery.
    Mahlumba P; Choonara YE; Kumar P; du Toit LC; Pillay V
    Molecules; 2016 Jul; 21(8):. PubMed ID: 27483234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral Delivery of Therapeutic Proteins and Peptides: An Overview of Current Technologies and Recommendations for Bridging from Approved Intravenous or Subcutaneous Administration to Novel Oral Regimens.
    Philippart M; Schmidt J; Bittner B
    Drug Res (Stuttg); 2016 Mar; 66(3):113-20. PubMed ID: 26536331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Converting peptides into drug leads by lipidation.
    Zhang L; Bulaj G
    Curr Med Chem; 2012; 19(11):1602-18. PubMed ID: 22376031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Nanotechnology in Delivery of Protein and Peptide Drugs.
    Patil S; Vhora I; Amrutiya J; Lalani R; Misra A
    Curr Pharm Des; 2015; 21(29):4155-73. PubMed ID: 26323432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics in veterinary medicine.
    Baggot JD
    Clin Pharmacokinet; 1992 Apr; 22(4):254-73. PubMed ID: 1606786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A liquid chromatography high-resolution mass spectrometry in vitro assay to assess metabolism at the injection site of subcutaneously administered therapeutic peptides.
    Esposito S; de Leonibus ML; Ingenito R; Bianchi E; Orsatti L; Monteagudo E
    J Pharm Biomed Anal; 2018 Sep; 159():449-458. PubMed ID: 30041153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans.
    Gao W; Jusko WJ
    Drug Metab Dispos; 2012 May; 40(5):990-7. PubMed ID: 22338110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I).
    Besunder JB; Reed MD; Blumer JL
    Clin Pharmacokinet; 1988 Apr; 14(4):189-216. PubMed ID: 3292100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.